Sonus (SNUS) Gets Slaughtered
Sonus Pharmaceuticals (SNUS) said that its drug candidate Tocosol Paclitaxel failed in a late-stage study aimed at treating breast cancer, according to AP. The company was trashed by investors, who moved it down 85% at the open to $.65. The…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Sonus Pharmaceuticals (SNUS) said that its drug candidate Tocosol Paclitaxel failed in a late-stage study aimed at treating breast cancer, according to AP.
The company was trashed by investors, who moved it down 85% at the open to $.65. The stock has a 52-week high of $6.32.
The company has always been a long shot. Last quarter, it lost $6.6 million on revenue of $3.3 million. But, the company had a market cap well over $200 million.
Not anymore.
Douglas A. McIntyre
Son
Contact [email protected] for any questions or corrections.







